Stress-related regulation of the kynurenine pathway: Relevance to neuropsychiatric and degenerative disorders

- This review assesses recent advances in determining a role for the kynurenine pathway (KP) in neurological disorders.
- This review examines the efficacy, or lack thereof, of pharmacological modulators of the KP in neurological disorders.
- This review identifies the need for further research to clarify if targeting the KP is a worthy pursuit therapeutically.

The kynurenine pathway (KP), which is activated in times of stress and infection has been implicated in the pathophysiology of neurodegenerative and psychiatric disorders. Activation of this tryptophan metabolising pathway results in the production of neuroactive metabolites which have the potential to interfere with normal neuronal functioning which may contribute to altered neuronal transmission and the emergence of symptoms of these brain disorders. This review investigates the involvement of the KP in a range of neurological disorders, examining recent in vitro, in vivo and clinical discoveries highlights evidence to indicate that the KP is a potential therapeutic target in both neurodegenerative and stress-related neuropsychiatric disorders. Furthermore, this review identifies gaps in our knowledge with regard to this field which are yet to be examined to lead to a more comprehensive understanding of the role of KP activation in brain health and disease.This article is part of the Special Issue entitled 'The Kynurenine Pathway in Health and Disease'.